CSL (CSLLY) Stock Price, News & Analysis

Company Overview

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions. The company also operates plasma collection centers that support the production of plasma-derived medicines.

CSL serves patients, healthcare providers and public-health systems in numerous markets worldwide, including Australia, North America, Europe and parts of Asia. The company is headquartered in Melbourne, Australia, and is led by Chief Executive Officer and Managing Director Paul McKenzie.

Key Stats

• Today's Range: $30.93 to $31.23
• 50-Day Range: $20.00 to $31.70
• 52-Week Range: $16.01 to $36.29
• Volume: 72,992 shs
• Average Volume: 128,104 shs
• Market Capitalization: $59.39 billion
• P/E Ratio: N/A
• Dividend Yield: 1.90%
• Price Target: N/A
• Consensus Rating: Hold

CSL Stock Analysis - MarketRank™

CSL scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

CSL has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

CSL has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.83%

Earnings Growth

Earnings for CSL are expected to grow by 10.83% in the coming year, from $1.57 to $1.74 per share.

Price to Earnings Growth Ratio

CSL has a PEG Ratio of 2.28. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

CSL has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of CSL has been sold short.

Short Interest Ratio / Days to Cover

CSL has a short interest ratio ("days to cover") of 1.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CSL has recently decreased by 32.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

CSL pays a meaningful dividend of 1.87%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

CSL does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, CSL will have a dividend payout ratio of 33.91% next year. This indicates that CSL will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.67

News Sentiment

CSL has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for CSL this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CSL insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.03% of the stock of CSL is held by institutions.

Company Calendar

• Today: 9/09/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:CSLLY
• CIK: 1274152
• Web: www.csl.com
• Phone: (139) 389-1911
• Fax: 61-3-9389-1434
• Employees: 29,904
• Year Founded: 1904

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 19.75
• P/E Growth: 2.28
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 2.57
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $15.80 billion
• Price / Sales: 3.76
• Cash Flow: $2.15 per share
• Price / Cash Flow: 14.43
• Book Value: $11.05 per share
• Price / Book: 2.81

Miscellaneous

• Outstanding Shares: 1,915,650,000
• Free Float: N/A
• Market Cap: $59.39 billion
• Optionable: Not Optionable
• Beta: 0.61